Published in Rev Endocr Metab Disord on March 01, 2010
Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study. Circ Heart Fail (2015) 2.02
Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic Biol Med (2010) 1.93
PGC-1 coactivators in cardiac development and disease. Circ Res (2010) 1.86
Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J Clin Invest (2012) 1.63
Thrombospondin-1 induction in the diabetic myocardium stabilizes the cardiac matrix in addition to promoting vascular rarefaction through angiopoietin-2 upregulation. Circ Res (2013) 1.61
Dietary obesity-associated Hif1α activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+ system. Genes Dev (2012) 1.59
Human resistin: found in translation from mouse to man. Trends Endocrinol Metab (2011) 1.51
Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol (2013) 1.29
Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets. Drug Discov Today Dis Mech (2010) 1.28
Inhibition of aldehyde dehydrogenase 2 by oxidative stress is associated with cardiac dysfunction in diabetic rats. Mol Med (2010) 1.23
Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid. Cardiovasc Diabetol (2012) 1.22
Oxidative stress and myocardial injury in the diabetic heart. J Pathol (2013) 1.18
GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc Res (2010) 1.14
Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3β dependent pathway in experimental diabetic cardiomyopathy. Cardiovasc Diabetol (2011) 1.11
Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes: a study in humans and rats. Circ Res (2012) 1.10
Diabetes and cardiac autonomic neuropathy: Clinical manifestations, cardiovascular consequences, diagnosis and treatment. World J Diabetes (2015) 1.08
Adaptation of myocardial substrate metabolism to a ketogenic nutrient environment. J Biol Chem (2010) 1.06
Predictors and prevention of diabetic cardiomyopathy. Diabetes Metab Syndr Obes (2013) 1.05
GSH or palmitate preserves mitochondrial energetic/redox balance, preventing mechanical dysfunction in metabolically challenged myocytes/hearts from type 2 diabetic mice. Diabetes (2012) 1.03
Cardiac dysfunction and oxidative stress in the metabolic syndrome: an update on antioxidant therapies. Curr Pharm Des (2013) 0.99
Protein kinase RNA-like endoplasmic reticulum kinase (PERK) signaling pathway plays a major role in reactive oxygen species (ROS)-mediated endoplasmic reticulum stress-induced apoptosis in diabetic cardiomyopathy. Cardiovasc Diabetol (2013) 0.99
Obesity-related alterations in cardiac lipid profile and nondipping blood pressure pattern during transition to diastolic dysfunction in male db/db mice. Endocrinology (2012) 0.99
Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats. Cardiovasc Diabetol (2011) 0.98
NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS One (2014) 0.97
Carbon monoxide improves cardiac function and mitochondrial population quality in a mouse model of metabolic syndrome. PLoS One (2012) 0.96
Protective effects of Acyl-coA thioesterase 1 on diabetic heart via PPARα/PGC1α signaling. PLoS One (2012) 0.95
Metabolic inflexibility and protein lysine acetylation in heart mitochondria of a chronic model of type 1 diabetes. Biochem J (2013) 0.94
Direct effects of adipokines on the heart: focus on adiponectin. Heart Fail Rev (2013) 0.92
Reactivation of fetal splicing programs in diabetic hearts is mediated by protein kinase C signaling. J Biol Chem (2013) 0.92
Sphingolipids in obesity, type 2 diabetes, and metabolic disease. Handb Exp Pharmacol (2013) 0.91
Low Intensity Physical Exercise Attenuates Cardiac Remodeling and Myocardial Oxidative Stress and Dysfunction in Diabetic Rats. J Diabetes Res (2015) 0.89
Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling. Mol Metab (2014) 0.89
Rad GTPase inhibits cardiac fibrosis through connective tissue growth factor. Cardiovasc Res (2011) 0.89
Myocardial adipose triglyceride lipase overexpression protects diabetic mice from the development of lipotoxic cardiomyopathy. Diabetes (2013) 0.89
The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am J Pathol (2011) 0.89
Resveratrol treatment reduces cardiac progenitor cell dysfunction and prevents morpho-functional ventricular remodeling in type-1 diabetic rats. PLoS One (2012) 0.89
Alteration of energy substrates and ROS production in diabetic cardiomyopathy. Mediators Inflamm (2013) 0.88
Diabetes-induced alterations in the extracellular matrix and their impact on myocardial function. Microsc Microanal (2012) 0.88
Exercise and diabetes have opposite effects on the assembly and O-GlcNAc modification of the mSin3A/HDAC1/2 complex in the heart. Cardiovasc Diabetol (2013) 0.87
Early cardiac changes in a rat model of prediabetes: brain natriuretic peptide overexpression seems to be the best marker. Cardiovasc Diabetol (2013) 0.87
Cardioprotection by controlling hyperamylinemia in a "humanized" diabetic rat model. J Am Heart Assoc (2014) 0.86
β3-Adrenoceptor activation relieves oxidative inhibition of the cardiac Na+-K+ pump in hyperglycemia induced by insulin receptor blockade. Am J Physiol Cell Physiol (2015) 0.85
A systematic review of fetal genes as biomarkers of cardiac hypertrophy in rodent models of diabetes. PLoS One (2014) 0.85
Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway. Clin Pharmacol Ther (2015) 0.85
Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats. Am J Physiol Heart Circ Physiol (2012) 0.84
Type II diabetes promotes a myofibroblast phenotype in cardiac fibroblasts. Life Sci (2013) 0.84
Alterations in sarcoplasmic reticulum and mitochondrial functions in diabetic cardiomyopathy. Exp Clin Cardiol (2012) 0.84
Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation (2016) 0.84
Endothelial function and left ventricular diastolic functional reserve in type 2 diabetes mellitus. Open Heart (2014) 0.84
Cardiac contractile function and mitochondrial respiration in diabetes-related mouse models. Cardiovasc Diabetol (2014) 0.83
Heart in diabetes: a microvascular disease. Diabetes Care (2011) 0.83
Restoring redox balance enhances contractility in heart trabeculae from type 2 diabetic rats exposed to high glucose. Am J Physiol Heart Circ Physiol (2014) 0.83
Subclinical Alterations of Cardiac Mechanics Present Early in the Course of Pediatric Type 1 Diabetes Mellitus: A Prospective Blinded Speckle Tracking Stress Echocardiography Study. J Diabetes Res (2015) 0.83
The absence of insulin signaling in the heart induces changes in potassium channel expression and ventricular repolarization. Am J Physiol Heart Circ Physiol (2013) 0.82
Ex vivo imaging of excised tissue using vital dyes and confocal microscopy. Curr Protoc Cytom (2012) 0.82
Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice. Am J Physiol Heart Circ Physiol (2015) 0.82
Role for high-glucose-induced protein O-GlcNAcylation in stimulating cardiac fibroblast collagen synthesis. Am J Physiol Cell Physiol (2014) 0.82
Mechanism of and therapeutic strategy for atrial fibrillation associated with diabetes mellitus. ScientificWorldJournal (2013) 0.81
Visceral adiposity is associated with altered myocardial glucose uptake measured by (18)FDG-PET in 346 subjects with normal glucose tolerance, prediabetes, and type 2 diabetes. Cardiovasc Diabetol (2015) 0.80
Long term liver specific glucokinase gene defect induced diabetic cardiomyopathy by up regulating NADPH oxidase and down regulating insulin receptor and p-AMPK. Cardiovasc Diabetol (2014) 0.80
Cardiospecific CD36 suppression by lentivirus-mediated RNA interference prevents cardiac hypertrophy and systolic dysfunction in high-fat-diet induced obese mice. Cardiovasc Diabetol (2015) 0.80
Subclinical Detection of Diabetic Cardiomyopathy with MicroRNAs: Challenges and Perspectives. J Diabetes Res (2015) 0.79
Protein kinase B (PKB/AKT1) formed signaling complexes with mitochondrial proteins and prevented glycolytic energy dysfunction in cultured cardiomyocytes during ischemia-reperfusion injury. Endocrinology (2014) 0.79
Prohibitin overexpression improves myocardial function in diabetic cardiomyopathy. Oncotarget (2016) 0.79
Dysregulation of RBFOX2 Is an Early Event in Cardiac Pathogenesis of Diabetes. Cell Rep (2016) 0.79
Factors affecting high-sensitivity cardiac troponin T elevation in Japanese metabolic syndrome patients. Diabetes Metab Syndr Obes (2015) 0.78
Methylglyoxal-Induced Endothelial Cell Loss and Inflammation Contribute to the Development of Diabetic Cardiomyopathy. Diabetes (2016) 0.78
Diastolic dysfunction in prediabetic male rats: Role of mitochondrial oxidative stress. Am J Physiol Heart Circ Physiol (2016) 0.78
Pathobiochemical changes in diabetic skeletal muscle as revealed by mass-spectrometry-based proteomics. J Nutr Metab (2012) 0.78
Sustained cardiac remodeling after a short-term very low calorie diet in type 2 diabetes mellitus patients. Int J Cardiovasc Imaging (2013) 0.78
Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+-Glucose Cotransport. J Am Heart Assoc (2015) 0.78
Protective mechanisms of mitochondria and heart function in diabetes. Antioxid Redox Signal (2015) 0.78
Riboflavin alleviates cardiac failure in Type I diabetic cardiomyopathy. Heart Int (2011) 0.78
Salusin-β contributes to oxidative stress and inflammation in diabetic cardiomyopathy. Cell Death Dis (2017) 0.77
Silent diabetic cardiomyopathy in everyday practice: a clinical and echocardiographic study. BMC Cardiovasc Disord (2016) 0.77
Malondialdehyde and 4-hydroxynonenal adducts are not formed on cardiac ryanodine receptor (RyR2) and sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA2) in diabetes. Mol Cell Biochem (2013) 0.77
Deletion of thioredoxin-interacting protein improves cardiac inotropic reserve in the streptozotocin-induced diabetic heart. Am J Physiol Heart Circ Physiol (2016) 0.77
Hypoglycemia: A Possible Link between Insulin Resistance, Metabolic Dyslipidemia, and Heart and Kidney Disease (the Cardiorenal Syndrome). Cardiorenal Med (2011) 0.77
Changes in left ventricular relaxation after azelnidipine treatment in hypertensive patients with diabetes: subanalysis of a prospective single-arm multicentre study. BMJ Open (2014) 0.77
Crosstalk between the heart and peripheral organs in heart failure. Exp Mol Med (2016) 0.77
DPP4 deficiency preserved cardiac function in abdominal aortic banding rats. PLoS One (2014) 0.77
The effects of green tea consumption on cardiometabolic alterations induced by experimental diabetes. Exp Diabetes Res (2012) 0.77
Monoamine Oxidases as Potential Contributors to Oxidative Stress in Diabetes: Time for a Study in Patients Undergoing Heart Surgery. Biomed Res Int (2015) 0.77
Hyperglycemia-Induced Hypovolemia Is Involved in Early Cardiac Magnetic Resonance Alterations in Streptozotocin-Induced Diabetic Mice: A Comparison with Furosemide-Induced Hypovolemia. PLoS One (2016) 0.76
Moderate intensity exercise prevents diabetic cardiomyopathy associated contractile dysfunction through restoration of mitochondrial function and connexin 43 levels in db/db mice. J Mol Cell Cardiol (2016) 0.76
High-risk diabetic patients with unprotected left main coronary artery disease: characteristics and medium-term outcomes of percutaneous revascularization with drug-eluting stents. Tex Heart Inst J (2011) 0.76
The effect of levosimendan on myocardial ischemia-reperfusion injury in streptozotocin-induced diabetic rats. Libyan J Med (2015) 0.76
Effect of Berberine on PPAR α /NO Activation in High Glucose- and Insulin-Induced Cardiomyocyte Hypertrophy. Evid Based Complement Alternat Med (2013) 0.76
Partial deficiency of HIF-1α stimulates pathological cardiac changes in streptozotocin-induced diabetic mice. BMC Endocr Disord (2014) 0.76
Left ventricular systolic function deterioration during dobutamine stress echocardiography as an early manifestation of diabetic cardiomyopathy and reversal by optimized therapeutic approach. Int J Cardiovasc Imaging (2011) 0.76
The Role of ERK1/2 in the Development of Diabetic Cardiomyopathy. Int J Mol Sci (2016) 0.75
Left ventricular diastolic reserve in patients with type 2 diabetes mellitus. Open Heart (2015) 0.75
Celecoxib prevents pressure overload-induced cardiac hypertrophy and dysfunction by inhibiting inflammation, apoptosis and oxidative stress. J Cell Mol Med (2015) 0.75
Evidence for distinct effects of exercise in different cardiac hypertrophic disorders. Life Sci (2015) 0.75
Do age, diabetes and left ventricular function affect the outcomes of ischemic mitral valve repair? Kardiochir Torakochirurgia Pol (2014) 0.75
Non-proliferative and Proliferative Lesions of the Cardiovascular System of the Rat and Mouse. J Toxicol Pathol (2016) 0.75
Cardiovascular Action of Insulin in Health and Disease: Endothelial L-Arginine Transport and Cardiac Voltage-Dependent Potassium Channels. Front Physiol (2016) 0.75
Diabetic Cardiomyopathy: An Immunometabolic Perspective. Front Endocrinol (Lausanne) (2017) 0.75
Hyperglycemia Induces Defective Ca2+ Homeostasis in Cardiomyocytes. Am J Physiol Heart Circ Physiol (2016) 0.75
Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases. J Diabetes Res (2016) 0.75
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
Diabetic cardiomyopathy revisited. Circulation (2007) 6.76
New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol (1972) 4.86
A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest (2001) 4.35
Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation (2002) 4.02
Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation (2007) 3.88
Insulin resistance and risk of congestive heart failure. JAMA (2005) 3.79
Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J (2004) 3.70
Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J Lipid Res (2006) 3.64
Impact of diabetes on cardiac structure and function: the strong heart study. Circulation (2000) 3.56
Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol (2008) 3.43
Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J Biol Chem (2001) 3.40
Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation (2003) 3.30
Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation (2005) 3.22
Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes (2007) 3.20
Myocardial cell death in human diabetes. Circ Res (2000) 3.12
Cardiac remodeling in obesity. Physiol Rev (2008) 2.95
Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res (2008) 2.88
Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol (2008) 2.74
Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation (2004) 2.73
Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest (1977) 2.53
Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest (2002) 2.53
Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology (2005) 2.43
A signalling role for 4-hydroxy-2-nonenal in regulation of mitochondrial uncoupling. EMBO J (2003) 2.43
Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med (2008) 2.42
Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes (2004) 2.39
Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest (2003) 2.39
Recipes for creating animal models of diabetic cardiovascular disease. Circ Res (2007) 2.34
Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol (2009) 2.20
Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol (1991) 2.19
Decreased cardiolipin synthesis corresponds with cytochrome c release in palmitate-induced cardiomyocyte apoptosis. J Biol Chem (2001) 2.05
Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation (2003) 2.01
Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology (2003) 1.99
Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation (2009) 1.91
Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol (2003) 1.80
Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond) (2004) 1.78
Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol (2002) 1.68
Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol (2006) 1.63
Lipotoxicity in the heart. Biochim Biophys Acta (2009) 1.60
Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res (2009) 1.58
Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes (2003) 1.56
Rodent models of diabetic cardiomyopathy. Dis Model Mech (2009) 1.56
Type 1 diabetic akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3. Diabetes (2008) 1.55
Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology (Bethesda) (2006) 1.53
Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation (2000) 1.53
Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag (2008) 1.49
Myocyte enhancer factor 2 (MEF2)-binding site is required for GLUT4 gene expression in transgenic mice. Regulation of MEF2 DNA binding activity in insulin-deficient diabetes. J Biol Chem (1998) 1.47
Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc Res (2009) 1.46
Tissue-specific remodeling of the mitochondrial proteome in type 1 diabetic akita mice. Diabetes (2009) 1.45
Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol (2009) 1.45
Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes (2006) 1.43
Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome. Clin Sci (Lond) (2008) 1.41
Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes (2002) 1.39
Rac1 is required for cardiomyocyte apoptosis during hyperglycemia. Diabetes (2009) 1.38
Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. Am J Physiol Heart Circ Physiol (2009) 1.38
Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol (2008) 1.35
Cardiac myocyte apoptosis is associated with increased DNA damage and decreased survival in murine models of obesity. Circ Res (2005) 1.30
Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res (1998) 1.29
Interval training normalizes cardiomyocyte function, diastolic Ca2+ control, and SR Ca2+ release synchronicity in a mouse model of diabetic cardiomyopathy. Circ Res (2009) 1.29
Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur Heart J (2009) 1.26
Screening for heart disease in diabetic subjects. Am Heart J (2005) 1.22
Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation (2004) 1.22
Collagen remodelling in myocardia of patients with diabetes. J Clin Pathol (1993) 1.19
Impaired cardiac contractile function in ventricular myocytes from leptin-deficient ob/ob obese mice. J Endocrinol (2006) 1.17
Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. Cardiovasc Res (2005) 1.17
Magnetic resonance imaging of progressive cardiomyopathic changes in the db/db mouse. Am J Physiol Heart Circ Physiol (2006) 1.15
Downregulation of myocardial myocyte enhancer factor 2C and myocyte enhancer factor 2C-regulated gene expression in diabetic patients with nonischemic heart failure. Circulation (2002) 1.15
Fatty acids and insulin modulate myocardial substrate metabolism in humans with type 1 diabetes. Diabetes (2007) 1.14
Comparative investigation of the left ventricular pressure-volume relationship in rat models of type 1 and type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol (2009) 1.14
The non-coding RNA gadd7 is a regulator of lipid-induced oxidative and endoplasmic reticulum stress. J Biol Chem (2009) 1.13
Flow mediated dilatation and cardiac function in type 1 diabetes mellitus. Am J Cardiol (2005) 1.13
Superoxide and respiratory coupling in mitochondria of insulin-deficient diabetic rats. Endocrinology (2008) 1.11
Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol (2002) 1.07
Left ventricular diastolic dysfunction in type 2 diabetes mellitus model rats. Am J Physiol Heart Circ Physiol (2002) 1.06
Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol (2008) 1.06
Dyslipidaemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness. Cardiovasc Res (2007) 1.04
Contractile dysfunction in hypertrophied hearts with deficient insulin receptor signaling: possible role of reduced capillary density. J Mol Cell Cardiol (2005) 1.03
Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol (1998) 1.00
Oxidative stress-dependent impairment of cardiac-specific transcription factors in experimental diabetes. Endocrinology (2006) 0.99
Obesity promotes left ventricular concentric rather than eccentric geometric remodeling and hypertrophy independent of blood pressure. Am J Hypertens (2008) 0.99
Decreased high-energy phosphate ratios in the myocardium of men with diabetes mellitus type I. J Cardiovasc Magn Reson (2002) 0.98
Location of arterial stiffening differs in those with impaired fasting glucose versus diabetes: implications for left ventricular hypertrophy from the Multi-Ethnic Study of Atherosclerosis. Diabetes (2009) 0.97
Type II diabetic mice exhibit contractile dysfunction but maintain cardiac output by favourable loading conditions. Eur J Heart Fail (2006) 0.96
Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Hypertens Res (2007) 0.96
Diabetes increases apoptosis and necrosis in both ischemic and nonischemic human myocardium: role of caspases and poly-adenosine diphosphate-ribose polymerase. J Thorac Cardiovasc Surg (2007) 0.96
TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes. J Cardiovasc Pharmacol (2009) 0.94
Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes. Diabetes Obes Metab (2007) 0.93
Impact of blood pressure and insulin on the relationship between body fat and left ventricular structure. Eur Heart J (2003) 0.93
Uncomplicated type 1 diabetes and preclinical left ventricular myocardial dysfunction: insights from echocardiography and exercise cardiac performance evaluation. Diabetes Res Clin Pract (2007) 0.93
Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered retinal vascular endothelial growth factor expression. Metabolism (2006) 0.85
Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study. Eur J Echocardiogr (2006) 0.82
Serum carboxy-terminal propeptide of type I procollagen (PIP) is a marker of diastolic dysfunction in patients with early type 2 diabetes mellitus. Int J Cardiol (2007) 0.82
Oxidative stress and fibrosis in incipient myocardial dysfunction in type 2 diabetic patients. Int J Cardiol (2005) 0.80
Relation among left ventricular mass, insulin resistance, and hemodynamic parameters in type 2 diabetes. Hypertens Res (2008) 0.80
Energy-preserving effects of IGF-1 antagonize starvation-induced cardiac autophagy. Cardiovasc Res (2011) 1.03
Insulin stimulates mitochondrial fusion and function in cardiomyocytes via the Akt-mTOR-NFκB-Opa-1 signaling pathway. Diabetes (2013) 1.01
Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation. Cardiovasc Res (2012) 0.89
Cardiomyocyte specific deletion of Crif1 causes mitochondrial cardiomyopathy in mice. PLoS One (2013) 0.81